RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (RGBM)-MedSci.cn

RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (RGBM)

Ahluwalia, M; Peereboom, D; Rauf, Y; Lathia, J; Alban, T; Schilero, C; Ciolfi, M; LaForest-Roys, C; Nayak, L; Lee, E; Wen, P; Reardon, D

NEURO-ONCOLOGY, 2020; 22 (): 35

科室
- - 订阅+
  - 更多科室
工具
服务